WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician–researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star [...] Read more »
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) — The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most [...] Read more »
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, [...] Read more »
Fortrea signe un accord définitif pour céder les activités Endpoint Clinical et Patient Access à Arsenal Capital Partners
Le projet de cession des activités Endpoint Clinical et Fortrea Patient Access permet à Fortrea de se recentrer sur son cœur de métier stratégique d’organisme de [...] Read more »
Fortrea unterzeichnet endgültige Vereinbarung zur Veräußerung der Geschäftsbereiche Endpoint Clinical und Patient Access an Arsenal Capital Partners
Vorgeschlagene Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access optimiert Fortreas strategische Ausrichtung als reines Auftragsforschungsinstitut
Read more »
Fortrea Assina Contrato Definitivo de Transferência das Unidades Endpoint Clinical e Patient Access para a Arsenal Capital Partners
A proposta da transferência das unidades Endpoint Clinical e Fortrea Patient Access agiliza ainda mais o foco estratégico da Fortrea como uma organização de pesquisa sob contrato
Read more »
Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure–play contract research organization
Read more »
Recursion Announces Plans to Open New Office in London
LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Read more »
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial [...] Read more »
Zenas BioPharma beruft Patricia Allen in den Verwaltungsrat
WALTHAM, Massachusetts, March 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, ein weltweit tätiges Biopharmazieunternehmen, dessen Ziel eine führende Rolle in der Entwicklung und Kommerzialisierung von [...] Read more »
Zenas BioPharma Nomeia Patricia Allen para o Conselho Diretor
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias voltadas [...] Read more »
Patricia Allen rejoint le Conseil d’administration de Zenas BioPharma
WALTHAM, Massachusetts, 07 mars 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la [...] Read more »
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology–directed [...] Read more »
Curia nomme Steve Lavezoli vice-président de sa division Produits biologiques
ALBANY, New York, 23 févr. 2024 (GLOBE NEWSWIRE) — Curia, l’un des principaux organismes de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui la nomination de [...] Read more »
Curia Nomeia Steve como Vice-Presidente, Divisão Biológica
ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje a nomeação de Steve [...] Read more »